tbuckley/cabot-search huggingface dataset:
202P The impact of statins and proton-pump inhibitors on immune checkpoint inhibition in patients with hepatocellular carcinoma
Authors: B. Hobeika, A.B. Philipp, I. Piseddu, K. Schondorff, S. Enssle, M. Karin, J. Schneider, F.P. Reiter, A. Geier, J. Mayerle, D.C. Rössler, E.N. De Toni, N. Ben Khaled
Journal: Annals of Oncology (2024)
193P The association between FGF19 expression and clinical outcomes in unresectable hepatocellular carcinoma (uHCC) patients (pts) receiving immune checkpoint inhibitor (ICI)-based therapies
Authors: Q. Cheng, T-A. Zhan, H-W. Huang, J-C. Zhan, R. Tao, Y-N. Li, X-P. Chen
Journal: Annals of Oncology (2024)
115P Exploratory analysis of angioregulatory microRNAs 27a, 27b, 107, and 622 in the progression of colorectal cancer
Authors: A. Koumarianou, A. Damalas, A. Ntavatzikos, K. Kamboli, P. Patapis, A. Rogdakis, G. Meimaris, P.G. Foukas, N. Arkadopoulos
Journal: Annals of Oncology (2024)
128P Real-world survival outcomes in MSS colorectal cancer(CRC) patients based on mesothelin(MSLN) expression
Authors: M. Malla, S.K. Deshmukh, S. Wu, T. Samec, M. Akce, D. Olevian, R. Elnaili, J. Xiu, A. Farrell, H.J. Lenz, E. Lou, S. Goel, D. Spetzler, R.M. Goldberg, L. Hazlehurst, B.F. El-Rayes
Journal: Annals of Oncology (2024)
203P Etiology as a prognostic factor for survival in hepatocellular carcinoma in Latin American population
Authors: S. Zilli Hernández, M.D.C. Diaz Romero, G. Calderillo Ruiz, B. Carbajal, M. Herrera Martinez, E. Ruiz, S.M. Miyagui Adame, D.L. Guerra Figueroa, E. Garcia Garcia
Journal: Annals of Oncology (2024)
117P Overcoming therapeutic resistance in colorectal cancer by inhibiting neutrophil extracellular traps
Authors: S. Gholami, E. Gazzara, J. Adrover, A. Liu, S. Han, Z. Aminzada, A. Rishi, C. Chung, C. Devoe, H. Huang, G. Vitiello, D. Deperalta, M. Weiss, S. Beyaz, E. Lou, A. Grothey, D. Tuveson, P. Westcott, M. Egeblad
Journal: Annals of Oncology (2024)
120P Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Characterization of the circulating immune response in the AVETUXIRI phase II trial
Authors: E. Benidovskaya, N. Huyghe, J. Carrasco, A. De Cuyper, I. Sinapi, E. Verstraelen, P. Goffette, B. Ghaye, M. Papier, A. van Maanen, M-L. Castella, J. Galon, M. van den Eynde
Journal: Annals of Oncology (2024)
116P Angiopietin-2 (Ang-2) as a potential biomarker for guiding prescription of bevacizumab (bev) or anti-EGFR in RAS/BRAF wild-type (wt) unresectable metastatic colorectal cancer (mCRC): An exploratory analysis of the STRATEGIC-1 GERCOR-PRODIGE phase III trial
Authors: C. Borg, L-M. Dourthe, T. André, J. Henriques, V. Bourgeois, P-L. Etienne, J. Desrame, E. Carola, O. Dupuis, N. Baba Hamed, D. Auby, C. Louvet, E. Maillard, O. Romano, C. Tournigand, M.L. Garcia Larnicol, E. Shacham Shmueli, F. Ghiringhelli, A. Degramont, B. Chibaudel
Journal: Annals of Oncology (2024)
139P Young onset colorectal cancer: Clinical and molecular characteristics
Authors: C. Cortas, G.M. Saridakis, I. Messaritakis, M. Karagianni, M. Chondrozoumaki, G. Tsironis, C. Matthaiou, I. Souglakos, D. Papamichael
Journal: Annals of Oncology (2024)
135P Exploring discrepancies in perception: A study of patients' and health professionals' understanding of cancer care
Authors: E. Christodoulis, P. Ntellas, K. Dadouli, L. Simpson, K.H.J. Lim, A. Shanthappa, J. Connell, J. Williams, D. Anderson, J. Hasan, S. Mullamitha, M. Braun, K. Marti, M. Adamou, M.P. Saunders, J. Barriuso, K.V. Kamposioras
Journal: Annals of Oncology (2024)
190P The role of liver biopsy for unsettled HCC diagnosis: A single-center experience
Authors: A. El Sergany, W. Elkashef, O. Abdallah, O. Elmetwally, R.A. Zayed, F. Sabry, M. Baghat, S. El-Etreby, M. Saad, M. Adel Elhawary, A.S. Hassan, A. Eissa, U. Shiha, K.M. Abouelkhair
Journal: Annals of Oncology (2024)
185P The combined role of patients (pts) gender and disease etiology on unresectable HCC (uHCC) first-line (1L) treatment outcome
Authors: S. Cesario, V. Genovesi, M. Rimini, T. Tada, G. Suda, S. Shimose, M. Kudo, F. Finkelmeier, C. Yoo, J. Presa, M.A. Iavarone, F. Marra, F.G. Foschi, E. Tamburini, S. Lonardi, F. Piscaglia, F. Salani, C. Vivaldi, A. Casadei Gardini, G. Masi
Journal: Annals of Oncology (2024)
171P A phase II study of ABSK-011 plus atezolizumab in patients with advanced hepatocellular carcinoma (HCC)
Authors: X-P. Chen, Y. Zhang, L. Zhao, J. Wu, T. Liang, J. Cai, X. Feng, Y. Qin, J. Wang, C. Hou, J. Lu, Z. Yan, H. Wang, H. Li, Q. Cheng
Journal: Annals of Oncology (2024)
136P Fertility and sexuality in early onset-colorectal cancer (EO-CRC) patients (pts): A monocentric survey
Authors: A. Spring, D. Barone, F. Schietroma, G. Caira, L. Chiofalo, V. Beccia, G. Trovato, A. Ceccarelli, S. Perazzo, L. Di Francesco, A. Cosmai, G. Valente, M. Chiaravalli, M. Bensi, C. Pozzo, M. Basso, L. Salvatore, M.A. Calegari, G. Tortora
Journal: Annals of Oncology (2024)
130P Oxaliplatin immune-induced syndrome (OIIS): A potentially life-threatening complication in colorectal cancer (CRC) patients (pts)
Authors: P. Vázquez-Revuelta, J.C. Ruffinelli Rodriguez, E. Casanovas-López, P. Álvarez-Sala, G. Molina-Molina, K. Molina-Mata, M. Martinez Villacampa, C. Santos Vivas, R. Lleonart-Bellfill
Journal: Annals of Oncology (2024)
133P The role of determining the diagnostic value of circulating tumor DNA (ctDNA) and natural blood killers (NK) in the diagnosis of precancerous diseases of the colon and colorectal cancer (CRC)
Authors: I. Turkpenova, D. Kaidarova, K.K. Smagulova, A. Jumanov, M. Orazgalieva, Z. Amankulov, R. Kadyrbaeva
Journal: Annals of Oncology (2024)
109P Prognostic genomic signatures in RAS/BRAF mutant (mut) metastatic colorectal cancer (mCRC) patients (pts) from the phase II study of NIVolumab (niv) plus FOLFOXIRI/Bevacizumab (bev) in first-line therapy of Advanced COloRectal cancer (NIVACOR- GOIRC-03-2018)
Authors: N. Normanno, A. Damato, R. Esposito Abate, S. Tessitore, F. Bergamo, L. Antonuzzo, G. Nasti, F. Pietrantonio, G. Tonini, T.P. Latiano, R. Bordonaro, G. Rosati, E. Giommoni, F. Iachetta, M. Larocca, E. Maiello, S. Lonardi, A. Romagnani, G. Maglietta, C. Pinto
Journal: Annals of Oncology (2024)
102P Real-world data on overall and progression-free survival for patients (pts) with metastatic colorectal cancer (mCRC) for the United Kingdom (UK) cohort of the PROMETCO study (PROMETCO-UK)
Authors: F.E. Marti Marti, R. Raman, D. Brady, G. Walker, A. Dewdney, S.C. Lau, R. Agarwal, J.A. Bridgewater, N. Lo, D. McLeod, M-A. Chauvet
Journal: Annals of Oncology (2024)
113P p16 immunohistochemical (IHC) expression (exp) predicts benefit from irinotecan in metastatic colorectal cancer (mCRC): A translational analysis of the TRIBE and TRIBE2 studies
Authors: V. Studiale, M.M. Germani, R. Moretto, V. Conca, F. Signorini, A. Proietti, M. Giordano, D. Rossini, A. Taravella, S. Murgioni, A. Russo, A. Passardi, T.P. Latiano, A. Zaniboni, G. Aprile, G. Di Paolo, F. Pietrantonio, C. Ugolini, C. Cremolini
Journal: Annals of Oncology (2024)
112P The presence of liver metastases does not predict resistance to immunotherapy in proficient MMR metastatic colorectal cancer (mCRC): A secondary analysis of the AtezoTRIBE study
Authors: M. Carullo, C. Antoniotti, D. Rossini, F. Marmorino, A. Raimondi, L. Salvatore, S. Lonardi, S. Tamberi, G. Vetere, M. Prisciandaro, F. Schietroma, M. Ramundo, C.C. Pircher, V. Conca, E. Perissinotto, A. Passardi, G. Aprile, C. Ugolini, J. Galon, C. Cremolini
Journal: Annals of Oncology (2024)
99P Circulating tumor DNA is prognostic for disease-free survival in patients with metastatic colorectal cancer undergoing definitive therapy
Authors: N. Naleid, K. Zablonski, C. Odonnell, T. Siripoon, M.L. Conces, M. Lumish, J.E. Selfridge, D. Bajor, S. Chakrabarti, Z. Jin, A. Mahipal
Journal: Annals of Oncology (2024)
108P Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A translational analysis of the TRIPLETE trial
Authors: V. Conca, M. Carullo, P. Vignali, D. Rossini, M.M. Germani, F. Bergamo, F. Pietrantonio, B. Borelli, F. Marmorino, M. Giordano, G. Randon, A. Taravella, R. Cerantola, A. Buonadonna, A. Cappetta, A. Zaniboni, L. Antonuzzo, G. Masi, C. Ugolini, C. Cremolini
Journal: Annals of Oncology (2024)
98P Intermittent first-line anti-EGFR with chemotherapy improves the survival of patients with RAS and BRAF wild type metastatic colon cancer
Authors: S. Kumar, A. Dewdney, R. Crossley, V. Wilshaw, H. Joyce, E. Koshy, A. Al-Khaldi, M. Khaira
Journal: Annals of Oncology (2024)
101P Predictive and prognostic factors of bone and brain metastases of metastatic colorectal cancer in the era of biomarker-driven therapy
Authors: K. Kataoka, Y. Fukumoto, K. Ito, K. Kimura, N. Beppu, J. Song, T. Matsubara, M. Otani, A. Imada, R. Kuwahara, Y. Horio, M. Uchino, H. Ikeuchi, M. Ikeda
Journal: Annals of Oncology (2024)
105P Prognostic value of PIK3CA gene assessment in tissue &amp; plasma in metastatic colorectal cancer (mCRC)
Authors: E. Terán Brage, R. Vidal Tocino, P. Reguera Puertas, Y. Lopez Mateos, Á. López Gutiérrez, M.M. Abad Hernández, J. Sayagues Manzano, A. Rodrigues, J. Montero-González, D. Morchón Araujo, J.C. Redondo González, R. Lozano Mejorada, E. Fonseca Sánchez
Journal: Annals of Oncology (2024)
111P Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES)
Authors: N. Normanno, A.M. Rachiglio, R. Esposito Abate, A. Orlandi, E. Maiello, G. Maglietta, A. Damato, M.R. Maiello, M. Carotenuto, M.A. Calegari, L. Antonuzzo, R. Bordonaro, M.G. Zampino, S. Tamberi, S. Lonardi, A. Avallone, T.P. Latiano, E. Tamburini, C.A. Barone, C. Pinto
Journal: Annals of Oncology (2024)
96P Gender-based differences in the efficacy of anti-EGFR/BRAF/MEK targeted therapy in patients with BRAF-mutated metastatic colorectal cancer: A gender-disaggregated analysis
Authors: L. Pala, T.M. De Pas, E. Cocorocchio, C.M. Catania, G.L. Ceresoli, D. Laszlo, E. Zattarin, F. Conforti
Journal: Annals of Oncology (2024)
110P Circulating tumor DNA (ctDNA) to detect acquired resistance to first-line (1L) treatment of RASWT metastatic colorectal cancer (mCRC): Insights from the PLATFORM-B study
Authors: V. Martelli, J. Vidal Barrull, C. Fernandez Rodriguez, P. García Alfonso, D. Paez, J. Gibert, V. Alonso, M.A. Gomez España, C. Santos Vivas, G. Duran Ogalla, M.E. Elez Fernandez, R. Garcia-Carbonero, R. Ferreiro Monteagudo, J.L. Manzano Mozo, F. Losa, B. Bellosillo Paricio, J. Tabernero, R. Salazar Soler, E. Aranda Aguilar, C. Montagut Viladot
Journal: Annals of Oncology (2024)
78P Sequential regorafenib (R) and trifluridine/tipiracil ± bevacizumab (T) in refractory metastatic colorectal cancer (mCRC) in US clinical practice: Subgroup analysis by tumor sidedness and metastatic site
Authors: D. Ahn, T. Bekaii-Saab, C. Yuan, X. Pan, H. Ostojic, F. Pisa
Journal: Annals of Oncology (2024)
25P PROgnostic Signature in stage II colon cancer (CC) patients enrolled in the phase III clinical trial TOSCA: PROSIT study
Authors: A. Puccini, L. Ferrando, L. Mazzarella, G. Frige, A. Pessino, A. Pastorino, V. Martelli, A. Garuti, A. Ballestrero, V. Torri, R. Labianca, M. Fassan, S. Lonardi, G. Zoppoli, A. Sobrero
Journal: Annals of Oncology (2024)
41P Surufatinib plus toripalimab and chemotherapy for second-line treatment of RAS/BRAF mutant (MT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC): A single-arm, phase II study (APHRODITE)
Authors: H. Zhang, L. Liu, X. Zhu, Y. Gao, Z. Tong, Q. Fu, X. Bao, X. Dai, P. Zhao, W. Fang, Y. Zheng
Journal: Annals of Oncology (2024)
30P Immunological markers of pathological and clinical and outcomes in mismatch repair deficient (MMRd) colorectal cancer (CRC)
Authors: B.R. Challoner, S.C. Slater, H.B. Sansano, M. Aresu, A. Bryant, H-C. Chen, R. Begum, T. Rana, O. Zhitkov, B. Leamon, L.J. Barber, C. Peckitt, I. Chau, N. Starling, D. Cunningham, M. Gerlinger
Journal: Annals of Oncology (2024)
53P Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase I TriComB study
Authors: P. Ciracì, V. Conca, R. Moretto, C. Antoniotti, M. Ambrosini, S. Murgioni, G. Gori, A. Russo, F. Bergamo, G. Randon, V. Studiale, E. Fini, F. Marmorino, B. Borelli, M.M. Germani, G. Vetere, M. Carullo, C. Boccaccio, G. Masi, C. Cremolini
Journal: Annals of Oncology (2024)
31P Effect of fruquintinib in patients with heavily pretreated metastatic colorectal cancer according to prognostic factors at baseline: Exploratory analysis of FRESCO-2
Authors: J. Tabernero, C. Eng, S. Lonardi, M.E. Elez Fernandez, T. Yoshino, A. Sobrero, J.C. Yao, A. Sartore Bianchi, V. Randrian, C. Cremolini, F. Ghiringhelli, H. Hochster, S. Kasper-Virchow, E. Van Cutsem, D. Arnold, D. Tougeron, H. Zhu, C. Dong, I. Carton, N.A. Dasari
Journal: Annals of Oncology (2024)
65P Costs and resource utilization in the curative and palliative treatment phases of metastatic colorectal cancer: Patient-level data analysis of the Finnish RAXO study
Authors: P.J. Osterlund, J. Kontiainen, K.I. Lehtomaki, T.T. Muhonen, E. Heerva, A. Algars, R. Ristamaki, H.P. Stedt, A. Lamminmäki, R. Kallio, T. Salminen, E. Osterlund, S. Aho, M.T. Barlund, P. Halonen, L-M. Soveri, A. Nordin, A. Uutela, B. Glimelius, H. Isoniemi
Journal: Annals of Oncology (2024)
80P Early onset metastatic colorectal cancer patients as an emerging distinctive clinical and molecular phenomenon
Authors: A. Pretta, P. Ziranu, E. Perissinotto, V. Nasca, F. Marmorino, R. Giampieri, M.C. De Grandis, P. Ciracì, M. Puzzoni, K. Cerma, C. Sciortino, A. Taravella, C. Damonte, V. Pusceddu, R. Berardi, S. Lonardi, F. Bergamo, F. Pietrantonio, C. Cremolini, M. Scartozzi
Journal: Annals of Oncology (2024)
77P Chronologic improvement in survival of first-line oxaliplatin based chemotherapy + targeted therapy for metastatic colorectal cancer (mCRC): Analysis of the ARCAD database
Authors: Y. Takeda, K. Yamazaki, L. Saltz, J-Y. Douillard, C.J.A. Punt, E. Van Cutsem, C. Bokemeyer, A. Venook, M. Koopman, V. Heinemann, C. Cremolini, J.R. Hecht, H.J.E-V. Schmoll, G. Nakayama, K. Sugihara, E. Oki, T. André, Q. Shi, A. De Gramont, T. Yoshino
Journal: Annals of Oncology (2024)
70P Intra-arterial hepatic chemotherapy in metastatic colorectal cancer: A successful method for oxaliplatin rechallenge?
Authors: E.J. El Rawadi, A. Boileve, L. Pierotti, A. Tarabay, E.A. Karam, M. Gelli, L. Tselikas, C. Smolenschi, T. de Baere, D. Malka, M. Valery, A. Hollebecque, V. Boige, M.P. Ducreux
Journal: Annals of Oncology (2024)
47P Does metastatic site influence the outcome in colorectal cancer patients treated with regorafenib? Insights from the phase II randomized study SOREGATT - PRODIGE 68 - UCGI 38
Authors: C. Smolenschi, M-L. Tanguy, M. Ben Abdelghani, A. Parzy, D. Tougeron, O. Bouche, J. Martin-Babau, J-B. Bachet, J. Taieb, J. Viaud, F. Khemissa Akouz, N. Fares, H. Castanie, N. Etchepare, W. Cacheux, C. Coutzac, D. Botsen, M. Mailleux, M.P. Ducreux, A. Boileve
Journal: Annals of Oncology (2024)
28P A mixed methods longitudinal process evaluation and implementation study of ctDNA use to guide adjuvant chemotherapy decision-making in patients with colorectal cancer: A sub-study of the ongoing UK wide interventional TRACC part C trial
Authors: E. Hainsworth, S. Stapleton, G. Ogara, T. Wiseman, S. Cruickshank, S.C. Slater, I. Chau, N. Starling, D. Cunningham
Journal: Annals of Oncology (2024)
63P FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only (LL), right-sided and/or RAS or BRAF mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials
Authors: F. Marmorino, C. Antoniotti, F.M. Meinert, F. Bergamo, G. Tonini, D. Rossini, B. Borelli, A. De Rosa, G. Allegrini, A. Stein, R. Moretto, M. Ronzoni, A. Zaniboni, M.M. Germani, S. Sperotto, E. Ongaro, F. Ghelardi, G. Masi, H.J.E-V. Schmoll, C. Cremolini
Journal: Annals of Oncology (2024)
29P Characterization of T cell responses induced by the individualized mRNA neoantigen vaccine autogene cevumeran in adjuvant stage II (high risk)/stage III colorectal cancer (CRC) patients (pts) from the biomarker cohort of the phase II BNT122-01 trial
Authors: M.E. Elez Fernandez, J. Maurel, V. Morris, S. Kopetz, B. Galligan, S. Ali, E. Derhovanessian, K. Unsal-Kacmaz, L. Manning, H. Henn, T. Weisenburger, M. Tonigold, P. Zurek, M. Fierek-Ulbig, A. Cortini, M. Pino Claveria, L. Preussner, F. Mueller, Ö. Türeci, U. Sahin
Journal: Annals of Oncology (2024)
76P Association of clinicopathological (C-P) features and tumor (tum) immune contexture with dissemination pattern in metastatic colorectal cancer (mCRC)
Authors: F. Salvà Ballabrera, E. Garcia-Galea, R. Comas, C. Salva de Torres, M. Rodriguez Castells, N. Saoudi Gonzalez, I. Baraibar Argota, F.J. Ros Montana, C. Vaghi, A. Garcia Rodriguez, A. Alcaraz, C. Dopazo, Z. Calixto, R. Querol, I. Macias Declara, J. Hernandez Yague, J. Cuadra-Urteaga, A. Vivancos, J. Tabernero, M.E. Elez Fernandez
Journal: Annals of Oncology (2024)
82P Interplay of high-risk human papillomaviruses and Epstein-Barr virus in advanced colorectal cancer
Authors: Q. Fernandes, S.P. Narayanan, J.S. Koshy, I. Gupta, K. Murshed, H. Abo Samra, V.P. Inchakalody, H. Al-Thawadi, S. Vranic, M. Merhi, M. Petkar, S. Uddin, S. Dermime, G.R. Babu, A-E. Al Moustafa
Journal: Annals of Oncology (2024)
87P Real-world evidence of FTD/TPI and bevacizumab combination therapy in metastatic colorectal cancer: Survival and clinicopathological insights
Authors: A. Koumarianou, A. Ntavatzikos, D. Symeonidis, K. Kamboli, E. Res, G. Papaxoinis, G. Vourli, N. Androulakis, I. Boukovinas, G. Oikonomopoulos, M. Giannakakou, C. Vallilas, S. Xynogalos, E. Samantas, M. Demiri, I. Souglakos, M.V. Karamouzis
Journal: Annals of Oncology (2024)
88P Real-world data of patients (pts) with BRAF V600E-mutated (mt) metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD–TPI)
Authors: F.J. Ros Montana, E. Garcia-Galea, P.G. Mugarza, R. Comas, G. Martini, F. Balconi, F. Salvà Ballabrera, I. Baraibar Argota, N. Saoudi Gonzalez, M. Rodriguez Castells, A. Alcaraz, A. Garcia Rodriguez, V. Alonso-Orduna, J. Tabernero, M.E. Elez Fernandez
Journal: Annals of Oncology (2024)
90P Predictive and prognostic factors in metastatic colorectal cancer patients treated with fruquintinib: A multicenter real-world analysis
Authors: C. Zhang, Y. Wang, J. Xu, M. Dong, K. Liu, Y. Lu, K. Chen, Y. Cao, H. Shi, Y. Bei, J. Li, J. Zhao, Y. Cao, N. Lu, H. Liu, P. Cai, K. Li, T. Yang, N. He, J. Dong
Journal: Annals of Oncology (2024)
85P Focus on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A real-world retrospective analysis
Authors: M.A. Calegari, V. Formica, F. Zoratto, G. Arrivi, A. Torsello, M. Polito, V. Picone, A. Emiliani, V. Cereda, M. Schirripa, G. Caira, A. Spring, G. Valente, C. Morelli, M. Rofei, C. Spoto, F. Mazzuca, A. Artemi, E. Dell'Aquila, L. Salvatore
Journal: Annals of Oncology (2024)
44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy
Authors: G.M. O'Kane, J. Spratlin, D-Y. Oh, S.Y. Rha, E. McWhirter, E. Elimova, P. Kavan, M.K. Choi, D. Kim, R.A. Goodwin, J.R. Hecht, D-H. Koo, K. Halani, R. McAllister, M. Jones, M.D. Snow, Y. Lemmerick, G. Spera, J. Pankovich
Journal: Annals of Oncology (2024)
57P Evaluating the patient-level association between progression-free survival and overall survival in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (MSI-H/dMMR mCRC) treated with immune checkpoint inhibitors
Authors: J.M.L. Roodhart, D.J. Sharpe, A.E. Tate, D. Bertwistle, M. Dixon, H-H. Chen, M. Kurt
Journal: Annals of Oncology (2024)
59P Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib 960mg (soto960) plus panitumumab (pani) vs trifluridine/tipiracil(T/T) plus bevacizumab (bev) in chemorefractory metastatic colorectal cancer (mCRC)
Authors: L. Salvatore, M. Fakih, Y. Kuboki, D.S. Hong, D.P. Modest, J. Taieb, T.J. Price, C. Cremolini, I.M. Majer, M. Rehn, E. Chan, Z. Chen, Q. Tran, F. Pietrantonio
Journal: Annals of Oncology (2024)
38P Modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for right-sided or BRAF mutant metastatic colorectal cancer (mCRC): Subgroup analysis of the DEEPER trial (JACCRO CC-13)
Authors: Y. Sunakawa, M. Shiozawa, T. Kawai, H. Ota, H. Yasui, M. Kochi, D. Manaka, H. Ohori, M. Matsuura, Y. Shinohara, M. Takeuchi, W. Ichikawa, M. Fujii, A. Tsuji
Journal: Annals of Oncology (2024)
52P Phase Ib study of pembrolizumab and XL888 in patients with advanced colorectal cancer
Authors: O. Alese, O.B. Gbolahan, A. McCook-Veal, K. Coleman, E. Greene, N. Horvat, J. Switchenko, G. Lesinski, B.F. El-Rayes
Journal: Annals of Oncology (2024)
71P Real-world treatment patterns in patients with metastatic colorectal cancer in the Netherlands
Authors: M.A.G. Elferink, F.N. van Erning, F.P.C. Sijtsma, L.B. Valkenburg-van Iersel, M.L. Wumkes, J.M.L. Roodhart, G.R. Vink
Journal: Annals of Oncology (2024)
33P Final analysis of the Greek cohort of the AGENT phase III study arfolitixorin in metastatic colorectal cancer
Authors: A. Koumarianou, E. Bournakis, A. Kotsakis, A. Ntavatzikos, K. Kamboli, N. Kentepozidis, L. Skintemo, R. Tell, C. Papadimitriou
Journal: Annals of Oncology (2024)
61P Safety and efficacy of encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: A systematic review and single-arm meta-analysis
Authors: D.S.G. Celso, M.L.R. Defante, V. Alzogaray, L.A. Torres, A.C. Melo Lopes, M. Bearse
Journal: Annals of Oncology (2024)
26P Response in patient-derived models recapitulates circulating tumor DNA clearance of matched colon cancer patients after adjuvant treatment in the PEGASUS trial
Authors: G. Mauri, E. Zanella, L. Lazzari, S. Scardellato, F. Cottino, R. Chilà, P. Luraghi, S. Rapisarda, J. Vidal Barrull, M.G. Zampino, A. Sartore Bianchi, M. Prisciandaro, M. Mandalà, A. Lorenzato, S. Ghezzi, S. Lonardi, S. Marsoni, A. Bardelli, S. Siena, L. Trusolino
Journal: Annals of Oncology (2024)
68P Post-treatment ctDNA analysis reveals patterns of HER2 therapy resistance in advanced HER2-amplified colorectal cancer
Authors: C. Hoyek, B. Zheng-Lin, O. Abidoye, D. Walden, C. Eslinger, M.B. Sonbol, C. Wu, D. Ahn, M. Borad, T. Bekaii-Saab
Journal: Annals of Oncology (2024)
50P Is liver transplantation a treatment option for unresectable colorectal liver metastases? Interim analysis of a phase II trial
Authors: L. Rajendran, C.T.J. Magyar, Z. Li, E. Winter, M. Cattral, B.A. Sayed, A. Ghanekar, N. Selzner, R. Burkes, G. Sapisochin
Journal: Annals of Oncology (2024)
92P Minor RAS mutations as predictors of survival in recurrent or metastatic colorectal cancer: A retrospective study in a single institution
Authors: Y. Kojitani, D. Sakai, Y. Amano, T. Ogata, M. Kitakaze, T. Sueda, T. Otsuka, M. Nishio, M. Ishihara, J. Nishimura, N. Sugimoto, T. Yagi, M. Yasui, T. Kudo
Journal: Annals of Oncology (2024)
93P Trifluridine-tipiracil (FTD/TPI) plus bevacizumab (BV) in patients (pts) with pretreated metastatic colorectal cancer (mCRC): A real-life Italian multicenter experience
Authors: G. Trovato, M. Carullo, F. Zoratto, S. Tamberi, F. Bergamo, M. Basso, M.A. Calegari, A. Puccini, A. Pastorino, M. Schirripa, J. Lucchetti, G. Arrivi, C. Morelli, K. Cerma, T. Troiani, F. Morano, C. Cremolini, E. Martinelli, G. Tortora, L. Salvatore
Journal: Annals of Oncology (2024)
34P Circulating tumor DNA (ctDNA) testing in tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the LIquid BIopsy monoclonal Antibodies (LIBImAb) study
Authors: A.M. Rachiglio, A. Sacco, D. Amoroso, S. Tufano, A. Damato, S. Tessitore, F. Pietrantonio, G.L. Frassineti, A. Pazzola, A. Colombo, L. Blasi, A. Sartore Bianchi, S. Tamberi, C. Carlomagno, M. Rossi, L. Antonuzzo, E. Gervasi, I. La Grotteria, N. Normanno, C. Pinto
Journal: Annals of Oncology (2024)